Current and ongoing progress in the therapy for resectable esophageal cancer |
| |
Authors: | C. R. Thomas Jr. |
| |
Affiliation: | Department of Radiation Oncology, University of Texas Health Science Center at San Antonio, San Antonio, Texas 78229-3900, USA. cthomas@ctrc.net |
| |
Abstract: | There have been recent advances in the surgical approach to respectable esophageal cancer. In addition, despite the paucity of level 1 data, regardless of histology (squamous cell or adenocarcinoma), neo-adjuvant chemoradiotherapy has evolved into a de facto standard of care for resectable disease. Pathologic response rate is a surrogate for a more favorable outcome. In addition, there are a number of molecularly targeted agents that may have clinical utility for these patients. Current clinical trials have been designed with a translational research component to define which patients may benefit from the incorporation of these novel agents alongside standard combined-modality approaches. |
| |
Keywords: | esophageal cancer |
|
|